Ra Capital Management, L.P. Purchases 41,319 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 41,319 shares of the firm’s stock in a transaction dated Friday, July 24th. The stock was acquired at an average price of $9.99 per share, with a total value of $412,776.81. Following the purchase, the director directly owned 17,283,802 shares of the company’s stock, valued at approximately $172,665,181.98. The trade was a 0.24% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.57 per share, for a total transaction of $3,351,032.83.

Artiva Biotherapeutics Trading Down 5.1%

Shares of ARTV stock opened at $10.00 on Thursday. Artiva Biotherapeutics, Inc. has a 12-month low of $2.22 and a 12-month high of $14.53. The firm’s 50 day moving average is $8.92 and its 200 day moving average is $7.45. The stock has a market capitalization of $247.10 million, a P/E ratio of -2.82 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

More Artiva Biotherapeutics News

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: RA Capital Management purchased an additional 41,319 ARTV shares at an average price of $9.99, investing approximately $413,000. This followed purchases of 59,880 shares on July 23, 84,124 shares on July 22, and 120,582 shares on July 21. The four transactions totaled roughly 306,000 shares and $3.0 million, increasing RA Capital’s ownership to more than 17.28 million shares. Continued insider accumulation can signal confidence in Artiva’s outlook and may provide a positive catalyst for the stock. Artiva Biotherapeutics director stock purchase report
• Positive Sentiment: Analyst coverage remains generally constructive. Artiva has an overall “Moderate Buy” rating and an average price target of $39, substantially above recent trading levels. Needham, Wedbush and Cantor Fitzgerald maintain bullish ratings, with Wedbush recently raising its target to $40. These targets reflect potential upside if Artiva’s off-the-shelf natural-killer-cell therapy pipeline advances successfully. Artiva Biotherapeutics analyst ratings
• Neutral Sentiment: Other institutional investors, including Bank of America, Jane Street, Qube Research & Technologies and Bridgeway Capital Management, have initiated or increased positions. However, the reported positions are relatively small and do not represent a major change in institutional ownership.
• Negative Sentiment: Artiva’s financial profile remains a risk. The company’s latest quarterly loss of $0.95 per share was worse than the $0.88 analyst consensus, and analysts expect a full-year loss of approximately $2.45 per share. Wall Street Zen and Weiss Ratings have issued sell-oriented views, underscoring concerns about ongoing cash needs, clinical execution and the absence of commercial revenue.

Analysts Set New Price Targets

A number of research firms have weighed in on ARTV. Wedbush increased their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC raised its holdings in Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after purchasing an additional 644,658 shares during the period. BNP Paribas Financial Markets lifted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Artiva Biotherapeutics by 46.8% during the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after purchasing an additional 37,053 shares during the period. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics during the fourth quarter valued at about $341,000. Finally, Jane Street Group LLC purchased a new stake in Artiva Biotherapeutics in the second quarter worth about $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.